This grant proposal is targeted at research problems arising in the early detection of cancer with special emphasis on the early diagnosis of breast cancer. The principal research areas include:(i) Develop a stochastic model for the disease progression of breast ductal carcinoma in situ (DCIS), (ii) Investigate the natural history of breast cancer, including methods for estimating the pre-clinical sojourn time and lead time distributions and (iii) Develop a new method for investigating the over diagnosis of disease. The diagnosis of breast DCIS in the U.S. has risen rapidly consistent with the dissemination of mammographic screening. Little is known about the natural history of DCIS. However women diagnosed with DCIS are known to be at elevated risk for invasive breast cancer (IBC). Knowledge on the natural history of DCIS, i.e. how it develops, if and when it will progress to IBC, would be an essential first step to the management of DCIS. Modeling the natural history of DCIS is challenging as there are no """"""""ideal"""""""" data on DCIS progression of untreated DCIS cases. The first main aim of this research is to develop a stochastic model to evaluate the DCIS progression process. This model will utilize the U.S. Surveillance Epidemiology and End Results (SEER) and Norwegian data. Another aim involves a theoretical investigation of the sojourn time distribution in the early stage of breast cancer and the lead time associated with early detection of cancer. The last aim develops a new method for over diagnosis estimation. It arises in the early detection of disease setting, by screening programs finding cases which would never have become clinical in one's life time. Currently the actual level of over diagnosis from breast cancer screening is in dispute. It is planned to develop a new statistical method for estimating over diagnosis. This method will be unique in that it will make use of the disease incidence data. Applications will be made using the data from the Norwegian Breast Cancer Screening Program. Overall the proposed research will contribute greatly to the management of DCIS in clinical practice and shed some light on ongoing debate of 'harms"""""""" of breast cancer screening.

Public Health Relevance

This research application investigates important issues in the early detection of breast cancer through stochastic modeling. The investigation on the natural history of breast ductal carcinoma in situ (DCIS) will greatly contribute to the management of DCIS in clinical practice. The proposed estimation method for over diagnosis (i.e., being diagnosed by screening which never be incident in one's life time) will shed some light in the ongoing debate of """"""""harms"""""""" of breast cancer screening.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA164301-01A1
Application #
8371645
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Stedman, Margaret R
Project Start
2012-08-03
Project End
2017-05-31
Budget Start
2012-08-03
Budget End
2013-05-31
Support Year
1
Fiscal Year
2012
Total Cost
$392,160
Indirect Cost
$141,455
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lee, Sandra J; Li, Xiaoxue; Huang, Hui et al. (2018) The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making 38:44S-53S
Najita, Julie S; Swetter, Susan M; Geller, Alan C et al. (2016) Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol 136:1894-1897
Mandelblatt, Jeanne S; Stout, Natasha K; Schechter, Clyde B et al. (2016) Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med 164:215-25
Munoz, Diego; Near, Aimee M; van Ravesteyn, Nicolien T et al. (2014) Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 106: